Genetically Engineered Mouse Models in Vaccine Development
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines, Clinical Advancement, and Associated Immunology".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 50
Special Issue Editors
Interests: hepatitis A, B, C, D and E
Special Issues, Collections and Topics in MDPI journals
Interests: immune cell development, differentiation and function; cross-talk between microbiota and immune system; fetal-maternal immunotolerance; human immune system mouse and its application in translational immunotherapy
Special Issue Information
Dear Colleagues,
Mice are the most common model for preclinical evaluation of vaccine safety and efficacy. However, there remain many challenges. Due to the strict host tropism, some pathogens do not naturally infect mice. Furthermore, the mouse immune system cannot reconstitute immune responses by humans. To overcome these problems, a number of recent studies have developed genetically engineered mice (GEM) to test vaccine security and immunogenicity.
The use of GEMs has exponentially increased, including knockout mice lacking a murine restriction factor, transgenic mice expressing a viral entry factor, and humanized immune system mice with reduced graft-versus-host disease and functional human B and T cells. These GEMs allow a more physiological study of human-restricted pathogens and novel vaccines.
In this Special Issue, we aim to introduce new GEM models and will discuss current progress and future perspectives related to these models in vaccinology. We look forward to receiving your contributions.
Dr. Bingqian Qu
Dr. Deshan Ren
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine
- immunogenicity
- knockout
- knockin
- transgenic mice
- humanized mice
- xenografts
- NCG/NKG/NRG/NSG
- viruses
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
